Efficacy and toxicity of intermediate-dose amphotericin B lipid complex as a primary or salvage treatment of fungal infections in patients with hematological malignancies

Leukemia and Lymphoma

Volumn 46, Issue 10, 2005, Pages 1429-1435

  Martino, Rodrigo ^a   Cortés, Montserrat ^a   Subirá, Maricel ^a   Parody, Rocio ^a   Moreno, Estela ^a   Sierra, Jorge ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

Abelcet; Amphotericin B; Fungal infections; Hematological malignancies

Indexed keywords

ALANINE AMINOTRANSFERASE; AMPHOTERICIN B LIPID COMPLEX; ANTINEOPLASTIC AGENT; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CREATININE; CYCLOSPORIN A; FLUCONAZOLE; ITRACONAZOLE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ACUTE LEUKEMIA; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; ASPERGILLOSIS; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANDIDIASIS; CHILL; CHRONIC LYMPHATIC LEUKEMIA; DEATH; DISEASE ASSOCIATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FEVER; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GRAFT REJECTION; HEMATOLOGIC MALIGNANCY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; MYCOSIS; MYELODYSPLASIA; NEPHROTOXICITY; NEUTROPENIA; PRIORITY JOURNAL; SALVAGE THERAPY; TREATMENT OUTCOME;

ADULT; AGED; AMPHOTERICIN B; ANTIBIOTICS, ANTIFUNGAL; FEMALE; HEMATOLOGIC NEOPLASMS; HUMANS; LIPIDS; MALE; MIDDLE AGED; MYCOSES; SALVAGE THERAPY;

EID: 26944439480     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.1080/10428190500205486     Document Type: Article

References (19)

1. Martino R, Subira M. Invasive fungal infections in hematology: new trends. Ann Hematol 2002;81:233-243.
2. Boucher HW, Groll AH, Chiou CC, Walsh TJ. Newer systemic antifungal agents: pharmacokinetics, safety and efficacy. Drugs 2004;64:1997-2020.
3. Martino R. Efficacy, safety and cost-effectiveness of Amphotericin B Upid Complex (ABLC): a review of the literature. Curr Med Res Opin 2004;20:485-504.
4. Subira M, Martino R, Gomez L, Marti JM, Estany C, Sierra J. Low-dose amphotericin B lipid complex vs. conventional amphotericin B for empirical antifungal therapy of neutropenic fever in patients with hematologic malignancies - a randomized, controlled trial. Eur J Haematol 2004;72:342-347.
5. Martino R, Subira M, Sureda A, Sierra J. Amphotericin B lipid complex at 3 mg/kg/day for treatment of invasive fungal infections in adults with haematological malignancies. J Antimicrob Chemother 1999;44:569-572.
6. Ascioglu S, Rex JH, de Pauw B, Bennett JE, Bille J, Crokaert F et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002;34:7-14.
7. Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann JW et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002;347:408-415.
8. Mora-Duarte J, Betts R, Rotstein C, Colombo AL, Thompson-Moya L, Smietana J et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002;347:2020-2029.
9. Fleming TR. One-sample multiple testing procedure for phase II clinical trials. Biometrics 1982;38:143-151.
10. Dupont B. Overview of the lipid formulations of amphotericin B. J Antimicrob Chemoth 2002;49(Suppl 1):31-36.
11. Walsh TJ, Goodman JL, Pappas P, Bekersky I, Buell DN, Roden M et al. Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study. Antimicrob Agents Chemother 2001;45:3487-496.
12. Ellis M, Spence D, de Pauw B, Meunier F, Marinus A, Collette L et al. An EORTC international multicenter randomized trial (EORTC number 19923) comparing two dosages of liposomal amphotericin B for treatment of invasive aspergillosis. Clin Infect Dis 1998;27:1406-1512.
13. Walsh TJ, Hiemenz JW, Seibel NL, Perfect JR, Horwith G, Lee L et al. Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin Infect Dis 1998;26:1383-1396.
14. Linden P, Lee L, Walsh TJ. Retrospective analysis of the dosage of amphotericin B lipid complex for the treatment of invasive fungal infections. Pharmacotherapy 1999;19:1261-1268.
15. Wingard JR, White MH, Anaissie E, Raffalli J, Goodman J, Arrieta A. A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L Amph/ABLC Collaborative Study Group. Clin Infect Dis 2000;31:1155-1163.
16. Eriksson U, Seifert B, Schaffner A. Comparison of effects of amphotericin B deoxycholate infused over 4 or 24 h: randomised controlled trial. Br Med J 2001;322:579-582.
17. Ioannidis JP, Haidich AB, Pappa M, Pantazis N, Kokori SI, Tektonidou MG et al. Comparison of evidence of treatment effects in randomized and nonrandomized studies. J Am Med Assoc 2001;286:821-830.
18. Kontoyiannis DP, Lewis RE. Toward more effective antifungal therapy: the prospects of combination therapy. Br J Haematol 2004;126:165-175.
19. Martino R, Chopra R, Dupont B et al. Phase I study of combination antifungal therapy with ABLC and caspofungin for empirical therapy of fungal infections in patients with hematological malignancy. Abstract of the 30th Meeting of the EBMT, Barcelona, Spain, 2004. Bone Marrow Transplant 2004;38(Suppl 1):356.